{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:40:56Z","timestamp":1792316456369,"version":"4.4.0"},"reference-count":222,"publisher":"Rockefeller University Press","issue":"8","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/rupress.org\/pages\/terms102024\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["ACS-25-1519593-01-YACS"],"award-info":[{"award-number":["ACS-25-1519593-01-YACS"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012639","name":"METAvivor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012639","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nellie B. Connally Research Funds"},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UM1 TR0045906"],"award-info":[{"award-number":["UM1 TR0045906"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Yosemite"}],"content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:p>Antibody\u2013drug conjugates (ADCs) have become an increasingly important component of the therapeutic landscape of many solid tumors. Currently, there are eight ADCs approved for solid tumors, with hundreds being developed and in clinical trials. Initially being approved in the advanced or metastatic settings, ADCs are also being incorporated as neoadjuvant or adjuvant therapies. In this review, we discuss the important components of ADC design in the context of clinical successes and failures. We further evaluate mechanisms of intrinsic and acquired resistance and strategies to overcome these barriers. Finally, we discuss the landscape of potential combination partners to increase efficacy of ADC therapies.<\/jats:p>","DOI":"10.1084\/jem.20252603","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:10:48Z","timestamp":1784898648000},"update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Antibody\u2013drug conjugates in solid tumors: Efficacy, challenges, and opportunities"],"prefix":"10.1084","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-2279","authenticated-orcid":true,"given":"Nakul M.","family":"Shah","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Division of Cancer Medicine, , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":true,"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 2 Department of Investigational Cancer Therapeutics, , Houston, TX,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2026072409103996300_bib1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1158\/2159-8290.CD-11-0320","article-title":"Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1","volume":"2","author":"Aarts","year":"2012","journal-title":"Cancer Discov."},{"key":"2026072409103996300_bib2","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","article-title":"IMGN853, a folate receptor-\u03b1 (FR\u03b1)\u2013Targeting antibody\u2013drug conjugate, exhibits potent targeted antitumor activity against FR\u03b1-expressing tumors","volume":"14","author":"Ab","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"2026072409103996300_bib3","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-23-0536","article-title":"Targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: A phase I clinical trial","volume":"29","author":"Abel","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"2026072409103996300_bib4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1200\/JCO.2024.42.16_suppl.1102","article-title":"Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study","volume":"42","author":"Abelman","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"2026072409103996300_bib5","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","article-title":"TOP1 mutations and cross-resistance to antibody\u2013drug conjugates in patients with metastatic breast cancer","volume":"31","author":"Abelman","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"2026072409103996300_bib6","first-page":"4750","article-title":"High affinity restricts the localization and tumor penetration of single-chain Fv antibody Molecules1","volume":"61","author":"Adams","year":"2001","journal-title":"Cancer Res."},{"key":"2026072409103996300_bib7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40364-023-00504-6","article-title":"Tissue factor (coagulation factor III): A potential double-edge molecule to be targeted and re-targeted toward cancer","volume":"11","author":"Ahmadi","year":"2023","journal-title":"Biomark. Res."},{"key":"2026072409103996300_bib8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non\u2013small cell lung cancer: The randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"2026072409103996300_bib9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10637-005-2907-z","article-title":"A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer","volume":"23","author":"Ajani","year":"2005","journal-title":"Invest. New Drugs"},{"key":"2026072409103996300_bib10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3390\/medicina61040719","article-title":"Comparison of clinicopathological characteristics for HER2-Null, HER2-Ultralow and HER2-low breast cancer: A single-center study","volume":"61","author":"Akay","year":"2025","journal-title":"Medicina (Kaunas)"},{"key":"2026072409103996300_bib11","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.2025.43.16_suppl.1041","article-title":"Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: A comprehensive multi-center study","volume":"43","author":"Alkassis","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"2026072409103996300_bib12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13058-017-0900-z","article-title":"Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers","volume":"19","author":"Baldassarre","year":"2017","journal-title":"Breast Cancer Res."},{"key":"2026072409103996300_bib13","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2026072409103996300_bib14","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer\u2606","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"2026072409103996300_bib15","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1200\/JCO.2023.41.16_suppl.1082","article-title":"Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+\/HER2\u2013 metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study","volume":"41","author":"Bardia","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"2026072409103996300_bib16","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"2026072409103996300_bib17","doi-asserted-by":"publisher","first-page":"17588359241248336","DOI":"10.1177\/17588359241248336","article-title":"TROPION-Breast03: A randomized phase III global trial of datopotamab deruxtecan \u00b1 durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy","volume":"16","author":"Bardia","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2026072409103996300_bib18","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1158\/1078-0432.CCR-24-0428","article-title":"Antibody\u2013drug conjugate sacituzumab govitecan enables a sequential TOP1\/PARP inhibitor therapy strategy in patients with breast cancer","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"2026072409103996300_bib19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor\u2013positive human epidermal growth factor receptor 2\u2013negative breast cancer: Primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"2026072409103996300_bib20","doi-asserted-by":"publisher","first-page":"113379","DOI":"10.1016\/j.ejca.2023.113379","article-title":"Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response","volume":"195","author":"Bosi","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"2026072409103996300_bib21","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-13-2440","article-title":"An antibody\u2013drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors","volume":"74","author":"Breij","year":"2014","journal-title":"Cancer Res."},{"key":"2026072409103996300_bib22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/blood.2021014663","article-title":"The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma","volume":"140","author":"Calabretta","year":"2022","journal-title":"Blood"},{"key":"2026072409103996300_bib23","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"2026072409103996300_bib24","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2\/SN-38 antibody\u2013drug conjugate: Characterization and efficacy in pancreatic, gastric, and other cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"2026072409103996300_bib25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s12967-025-06434-1","article-title":"LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth","volume":"23","author":"Cela","year":"2025","journal-title":"J. Transl. Med."},{"key":"2026072409103996300_bib222","article-title":"FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer","author":"Center for Drug Evaluation and Research","year":"2025","journal-title":"Food and Drug Administration"},{"key":"2026072409103996300_bib27","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody\u2013drug conjugate targeting Nectin-4 Is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"key":"2026072409103996300_bib28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172156","article-title":"Antibody-drug conjugates in breast cancer: Overcoming resistance and boosting immune response","volume":"133","author":"Chang","year":"2023","journal-title":"J. Clin. Invest."},{"key":"2026072409103996300_bib29","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: An emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"2026072409103996300_bib30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1158\/2159-8290.CD-25-0647","article-title":"Trastuzumab Deruxtecan (T-DXd) resistance via loss of HER2 expression and binding","volume":"16","author":"Chen","year":"2025","journal-title":"Cancer Discov."},{"key":"2026072409103996300_bib31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/abt\/tbaf004","article-title":"Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors","volume":"8","author":"Cheng","year":"2025","journal-title":"Antib. Ther."},{"key":"2026072409103996300_bib32","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"key":"2026072409103996300_bib33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1083\/jcb.200701086","article-title":"c-Met is essential for wound healing in the skin","volume":"177","author":"Chmielowiec","year":"2007","journal-title":"J. Cell Biol."},{"key":"2026072409103996300_bib34","doi-asserted-by":"publisher","first-page":"zcab003","DOI":"10.1093\/narcan\/zcab003","article-title":"Top1-PARP1 association and beyond: From DNA topology to break repair","volume":"3","author":"Chowdhuri","year":"2021","journal-title":"NAR Cancer"},{"key":"2026072409103996300_bib35","doi-asserted-by":"publisher","first-page":"1882028","DOI":"10.1080\/19420862.2021.1882028","article-title":"Coming together at the hinges: Therapeutic prospects of IgG3","volume":"13","author":"Chu","year":"2021","journal-title":"mAbs"},{"key":"2026072409103996300_bib36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133072","article-title":"Caveolin-1 Dependent endocytosis enhances the chemosensitivity of HER-2 positive breast cancer cells to trastuzumab Emtansine (T-DM1)","volume":"10","author":"Chung","year":"2015","journal-title":"PLoS One"},{"key":"2026072409103996300_bib37","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1074\/jbc.M106287200","article-title":"S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function","volume":"277","author":"Cliby","year":"2002","journal-title":"J. Biol. Chem."},{"key":"2026072409103996300_bib38","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov."},{"key":"2026072409103996300_bib39","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","article-title":"The therapeutic window of antibody drug conjugates: A dogma in need of revision","volume":"40","author":"Colombo","year":"2022","journal-title":"Cancer Cell"},{"key":"2026072409103996300_bib40","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The Journey of antibody\u2013drug conjugates: Lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov."},{"key":"2026072409103996300_bib41","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.annonc.2026.04.008","article-title":"Re-evaluating antibody-drug conjugate linker stability: Assessment, interpretation, and clinical translation","volume":"0","author":"Colombo","year":"2026","journal-title":"Ann. Oncol."},{"key":"2026072409103996300_bib42","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"2026072409103996300_bib43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/d41573-025-00185-w","article-title":"Innovative antibody therapeutic development in China compared with the USA and Europe","volume":"25","author":"Crescioli","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"2026072409103996300_bib44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293703","article-title":"Reducing target binding affinity improves the therapeutic index of anti-MET antibody-drug conjugate in tumor bearing animals","volume":"19","author":"Datta-Mannan","year":"2024","journal-title":"PLoS One"},{"key":"2026072409103996300_bib45","doi-asserted-by":"publisher","first-page":"CT071","DOI":"10.1158\/1538-7445.AM2025-CT071","article-title":"Abstract CT071: Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495)","volume":"85","author":"Davis","year":"2025","journal-title":"Cancer Res."},{"key":"2026072409103996300_bib46","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1699","article-title":"Systematic study of tissue factor expression in solid tumors","volume":"6","author":"de Bono","year":"2023","journal-title":"Cancer Rep."},{"key":"2026072409103996300_bib47","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.03.008","article-title":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): A randomised, open-label, international, phase III trial","author":"Dent","year":"2026","journal-title":"Ann. Oncol."},{"key":"2026072409103996300_bib48","doi-asserted-by":"publisher","first-page":"100753","DOI":"10.1016\/j.modpat.2025.100753","article-title":"Spatial expression of HER2, NECTIN4, and TROP-2 in muscle-invasive bladder cancer and metastases: Implications for pathological and clinical management","volume":"38","author":"Dernbach","year":"2025","journal-title":"Mod. Pathol."},{"key":"2026072409103996300_bib49","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.1158\/1078-0432.CCR-23-0103","article-title":"Adavosertib enhances antitumor activity of trastuzumab deruxtecan in HER2-expressing cancers","volume":"29","author":"DiPeri","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"2026072409103996300_bib50","doi-asserted-by":"publisher","first-page":"B009","DOI":"10.1158\/1535-7163.TARG-25-B009","article-title":"Abstract B009: Trial in progress: Phase 1 study of trastuzumab deruxtecan (DS-8201a) in combination with azenosertib (ZN-c3) in HER2-expressing\/amplified gastric\/gastroesophageal junction cancer and other solid tumors with HER2 expression","volume":"24","author":"Doerfler","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"2026072409103996300_bib51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1021\/bc9002019","article-title":"Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies","volume":"21","author":"Ducry","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"2026072409103996300_bib52","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","article-title":"Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing","volume":"66","author":"Erickson","year":"2006","journal-title":"Cancer Res."},{"key":"2026072409103996300_bib53","doi-asserted-by":"publisher","first-page":"858865","DOI":"10.3389\/fonc.2022.858865","article-title":"Head-to-head comparison of the expression differences of NECTIN-4, TROP-2, and HER2 in urothelial carcinoma and its histologic variants","volume":"12","author":"Fan","year":"2022","journal-title":"Front. Oncol."},{"key":"2026072409103996300_bib54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/abt\/tbaf010","article-title":"A review of conjugation technologies for antibody drug conjugates","volume":"8","author":"Fan","year":"2025","journal-title":"Antib. Ther."},{"key":"2026072409103996300_bib55","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","article-title":"Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: Phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab","volume":"11","author":"Filho","year":"2021","journal-title":"Cancer Discov."},{"key":"2026072409103996300_bib56","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/modpathol.3801001","article-title":"TROP2: A novel prognostic marker in squamous cell carcinoma of the oral cavity","volume":"21","author":"Fong","year":"2008","journal-title":"Mod. Pathol."},{"key":"2026072409103996300_bib57","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/cdd.2009.107","article-title":"Apoptosis and glutathione: Beyond an antioxidant","volume":"16","author":"Franco","year":"2009","journal-title":"Cell Death Differ."},{"key":"2026072409103996300_bib58","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.annonc.2024.07.245","article-title":"Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational breast cancer research consortium trial 022","volume":"35","author":"Freedman","year":"2024","journal-title":"Ann. Oncol."},{"key":"2026072409103996300_bib59","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: The \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"2026072409103996300_bib60","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1200\/JCO.22.00830","article-title":"Multicenter Phase II trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring CCNE1 amplification","volume":"41","author":"Fu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"2026072409103996300_bib61","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody-drug conjugates: In search of partners of choice","volume":"9","author":"Fuentes-Antr\u00e1s","year":"2023","journal-title":"Trends Cancer"},{"key":"2026072409103996300_bib62","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1158\/2767-9764.CRC-24-0248","article-title":"Mechanistic characterization of cancer-associated fibroblast depletion via an antibody-drug conjugate targeting fibroblast activation protein","volume":"4","author":"Gallant","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"2026072409103996300_bib226","doi-asserted-by":"publisher","first-page":"S1556","DOI":"10.1016\/j.annonc.2025.09.021","article-title":"LBA1 Trastuzumab Deruxtecan (T-DXd) vs Trastuzumab Emtansine (T-DM1) in Patients (Pts) with high-risk human epidermal growth factor receptor 2\u2013positive (HER2+) primary Breast Cancer (BC) with residual invasive disease after Neoadjuvant Therapy (Tx): interim analysis of DESTINY-Breast05","volume":"36","author":"Geyer","year":"2025","journal-title":"Ann. Oncol."},{"key":"2026072409103996300_bib64","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: Primary results from the randomized, Phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"2026072409103996300_bib65","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3233\/KCA-230012","article-title":"Emerging antibody-drug conjugate therapies and targets for metastatic renal cell carcinoma","volume":"7","author":"Gottlich","year":"2023","journal-title":"Kidney Cancer"},{"key":"2026072409103996300_bib66","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1161\/ATVBAHA.117.309846","article-title":"Tissue factor","volume":"38","author":"Grover","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2026072409103996300_bib67","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: Making 1+1&gt;2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"2026072409103996300_bib68","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/0008-5472.CAN-15-1610","article-title":"SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm","volume":"75","author":"Hamblett","year":"2015","journal-title":"Cancer Res."},{"key":"2026072409103996300_bib69","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/ph14070674","article-title":"Impact of endocytosis mechanisms for the receptors targeted by the currently approved Antibody-Drug Conjugates (ADCs)\u2014A necessity for future adc research and development","volume":"14","author":"Hammood","year":"2021","journal-title":"Pharmaceuticals"},{"key":"2026072409103996300_bib224","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.","volume":"37","author":"Harbeck","year":"2026","journal-title":"Ann. Oncol."},{"key":"2026072409103996300_bib71","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/14712598.2020.1776255","article-title":"Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy","volume":"21","author":"Hartley","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"2026072409103996300_bib72","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3390\/cancers15051524","article-title":"The tissue factor pathway in cancer: Overview and role of heparan sulfate proteoglycans","volume":"15","author":"Hassan","year":"2023","journal-title":"Cancers"},{"key":"2026072409103996300_bib73","doi-asserted-by":"publisher","first-page":"102720","DOI":"10.1016\/j.ctrv.2024.102720","article-title":"Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan","volume":"125","author":"Heist","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"2026072409103996300_bib74","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1158\/1078-0432.CCR-04-0088","article-title":"A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors","volume":"10","author":"Helft","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"2026072409103996300_bib75","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1158\/1078-0432.CCR-21-3261","article-title":"Anti-CD79B Antibody\u2013drug conjugate DCDS0780A in patients with B-Cell non-hodgkin lymphoma: Phase 1 dose-escalation study","volume":"28","author":"Herrera","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"2026072409103996300_bib76","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1395127","article-title":"Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)","volume":"7","author":"Hoffmann","year":"2017","journal-title":"Oncoimmunology"},{"key":"2026072409103996300_bib77","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1158\/1538-7445.AM2025-3790","article-title":"Abstract 3790: Preclinical assessment of valemetostat, a dual inhibitor of EZH2 and EZH1, combined with trastuzumab deruxtecan and datopotamab deruxtecan for multiple solid tumors","volume":"85","author":"Honma","year":"2025","journal-title":"Cancer Res."},{"key":"2026072409103996300_bib78","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1535-7163.MCT-22-0099","article-title":"Anti-extra domain B splice variant of fibronectin antibody\u2013drug conjugate eliminates tumors with enhanced efficacy when combined with checkpoint blockade","volume":"21","author":"Hooper","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"2026072409103996300_bib79","doi-asserted-by":"publisher","first-page":"1175563","DOI":"10.3389\/fonc.2023.1175563","article-title":"Association between pH regulation of the tumor microenvironment and immunological state","volume":"13","author":"Hosonuma","year":"2023","journal-title":"Front. Oncol."},{"key":"2026072409103996300_bib80","doi-asserted-by":"publisher","first-page":"13004","DOI":"10.1021\/acs.jmedchem.1c01121","article-title":"Discovery of ZN-c3, a highly potent and selective Wee1 inhibitor undergoing evaluation in clinical trials for the treatment of cancer","volume":"64","author":"Huang","year":"2021","journal-title":"J. Med. Chem."},{"key":"2026072409103996300_bib81","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13046-025-03407-6","article-title":"HHLA2 activates c-Met and identifies patients for targeted therapy in hepatocellular carcinoma","volume":"44","author":"Huang","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2026072409103996300_bib82","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41523-025-00748-5","article-title":"Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)","volume":"11","author":"Huppert","year":"2025","journal-title":"Npj Breast Cancer"},{"key":"2026072409103996300_bib83","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","article-title":"A HER2-targeting antibody\u2013Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model","volume":"17","author":"Iwata","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"2026072409103996300_bib84","doi-asserted-by":"publisher","first-page":"6968","DOI":"10.1158\/0008-5472.CAN-13-3369","article-title":"ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase I inhibitors by disabling DNA replication initiation and fork elongation responses","volume":"74","author":"Joss\u00e9","year":"2014","journal-title":"Cancer Res."},{"key":"2026072409103996300_bib85","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/ph13090245","article-title":"Antibody-drug conjugates: The last decade","volume":"13","author":"Joubert","year":"2020","journal-title":"Pharmaceuticals"},{"key":"2026072409103996300_bib86","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1021\/bc100480a","article-title":"Disulfide-linked antibody-maytansinoid conjugates: Optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage","volume":"22","author":"Kellogg","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"2026072409103996300_bib87","doi-asserted-by":"publisher","first-page":"115608","DOI":"10.1016\/j.addr.2025.115608","article-title":"Maximizing therapeutic potential and safety: Exploring multi\/dual-payload antibody conjugates as cancer theranostics","volume":"222","author":"Khosravifarsani","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2026072409103996300_bib88","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.1158\/1078-0432.CCR-18-1300","article-title":"SLC46A3 as a potential predictive biomarker for antibody\u2013drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads","volume":"24","author":"Kinneer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"2026072409103996300_bib89","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/bjc.2014.567","article-title":"Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: Implications for clinical testing. An ovarian tumour tissue analysis consortium study","volume":"111","author":"K\u00f6bel","year":"2014","journal-title":"Br. J. Cancer."},{"key":"2026072409103996300_bib90","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"The Oncologist"},{"key":"2026072409103996300_bib91","doi-asserted-by":"publisher","first-page":"6949","DOI":"10.1021\/jm500766w","article-title":"Ado-trastuzumab Emtansine (T-DM1): An antibody-drug conjugate (ADC) for HER2-positive breast cancer","volume":"57","author":"Lambert","year":"2014","journal-title":"J. Med. Chem."},{"key":"2026072409103996300_bib92","doi-asserted-by":"publisher","first-page":"101738","DOI":"10.1016\/j.gore.2025.101738","article-title":"Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer","volume":"59","author":"Lang","year":"2025","journal-title":"Gynecol. Oncol. Rep."},{"key":"2026072409103996300_bib93","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1002\/dvdy.21794","article-title":"hgf\/c-met expression and functional analysis during zebrafish embryogenesis","volume":"237","author":"Latimer","year":"2008","journal-title":"Dev. Dyn."},{"key":"2026072409103996300_bib94","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2025.08.002","article-title":"Radiolabeled Antibody-drug conjugates in the treatment of solid tumors","author":"Lawal","year":"2025","journal-title":"Semin. Nucl. Med."},{"key":"2026072409103996300_bib95","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202500262","article-title":"Linker design for the antibody drug conjugates: A comprehensive review","volume":"20","author":"Lei","year":"2025","journal-title":"ChemMedChem"},{"key":"2026072409103996300_bib96","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1158\/1535-7163.MCT-17-0296","article-title":"Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"2026072409103996300_bib97","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","article-title":"HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discov."},{"key":"2026072409103996300_bib98","doi-asserted-by":"publisher","first-page":"560615","DOI":"10.3389\/fonc.2020.560615","article-title":"Spectrum of Mesenchymal-epithelial transition aberrations and potential clinical implications: Insights from integrative pancancer analysis","volume":"10","author":"Li","year":"2020","journal-title":"Front. Oncol."},{"key":"2026072409103996300_bib99","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1200\/JCO.2023.41.16_suppl.2538","article-title":"A phase 1\/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors","volume":"41","author":"Li","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"2026072409103996300_bib100","doi-asserted-by":"publisher","first-page":"1354543","DOI":"10.3389\/fonc.2024.1354543","article-title":"Therapeutic prospects of nectin-4 in cancer: Applications and value","volume":"14","author":"Li","year":"2024","journal-title":"Front. Oncol."},{"key":"2026072409103996300_bib101","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody\u2013drug conjugates: A review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B."},{"key":"2026072409103996300_bib102","first-page":"1765","article-title":"FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models","volume":"7","author":"Ling","year":"2015","journal-title":"Am. J. Transl. Res."},{"key":"2026072409103996300_bib103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075864","article-title":"Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"2026072409103996300_bib104","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/1354750X.2020.1771420","article-title":"A systematic review and meta-analysis of higher expression of folate receptor alpha (FOLR1) predicts poor cancer prognosis","volume":"25","author":"Liu","year":"2020","journal-title":"Biomarkers"},{"key":"2026072409103996300_bib105","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220126","article-title":"HER2 drives lung fibrosis by activating a metastatic cancer signature in invasive lung fibroblasts","volume":"219","author":"Liu","year":"2022","journal-title":"J. Exp. Med."},{"key":"2026072409103996300_bib106","doi-asserted-by":"publisher","first-page":"116329","DOI":"10.1016\/j.ejmech.2024.116329","article-title":"Cathepsin B: The dawn of tumor therapy","volume":"269","author":"Liu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"2026072409103996300_bib107","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1200\/JCO-24-01606","article-title":"ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of Adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma","volume":"43","author":"Liu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"2026072409103996300_bib108","doi-asserted-by":"publisher","first-page":"2470309","DOI":"10.1080\/19420862.2025.2470309","article-title":"Folate receptor alpha for cancer therapy: An antibody and antibody-drug conjugate target coming of age","volume":"17","author":"Liu","year":"2025","journal-title":"MAbs"},{"key":"2026072409103996300_bib109","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab-maytansinoid antibody\u2013drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"2026072409103996300_bib110","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1056\/NEJMoa2514661","article-title":"Trastuzumab Deruxtecan in residual HER2-positive early breast cancer","volume":"394","author":"Loibl","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"2026072409103996300_bib111","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: Updated safety and efficacy outcomes","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann. Oncol."},{"key":"2026072409103996300_bib112","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40164-025-00624-9","article-title":"Development of a bispecific antibody-drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors","volume":"14","author":"Luo","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"2026072409103996300_bib113","doi-asserted-by":"publisher","first-page":"S225","DOI":"10.1016\/j.annonc.2024.08.044","article-title":"35P the selective WEE1 inhibitor azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I inhibitor-based antibody drug conjugates","volume":"35","author":"Ma","year":"2024","journal-title":"Ann. Oncol."},{"key":"2026072409103996300_bib114","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-24-1194","article-title":"Azenosertib is a potent and selective WEE1 kinase inhibitor with broad antitumor activity across a range of solid tumors","volume":"24","author":"Ma","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"2026072409103996300_bib115","doi-asserted-by":"publisher","first-page":"2229101","DOI":"10.1080\/19420862.2023.2229101","article-title":"Exploration of the antibody\u2013drug conjugate clinical landscape","volume":"15","author":"Maecker","year":"2023","journal-title":"MAbs"},{"key":"2026072409103996300_bib116","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.3390\/cancers12113323","article-title":"Mechanisms of taxane resistance","volume":"12","author":"Maloney","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026072409103996300_bib117","doi-asserted-by":"publisher","first-page":"2500305","DOI":"10.1002\/cbic.202500305","article-title":"Advanced antibody\u2013drug conjugates design: Innovation in linker chemistry and site-specific conjugation technologies","volume":"26","author":"Matsuda","year":"2025","journal-title":"Chembiochem"},{"key":"2026072409103996300_bib118","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma\u2606","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann. Oncol."},{"key":"2026072409103996300_bib119","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 Phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"2026072409103996300_bib120","doi-asserted-by":"publisher","first-page":"oyaf031","DOI":"10.1093\/oncolo\/oyaf031","article-title":"Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis\/stomatitis","volume":"30","author":"Meric-Bernstam","year":"2025","journal-title":"Oncol."},{"key":"2026072409103996300_bib121","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.1038\/s41467-022-33123-0","article-title":"Mechanistic understanding of human SLFN11","volume":"13","author":"Metzner","year":"2022","journal-title":"Nat. Commun."},{"key":"2026072409103996300_bib122","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/onc.2010.532","article-title":"Ligand independent activation of c-Met by fibronectin and \u03b15\u03b21-integrin regulates ovarian cancer invasion and metastasis","volume":"30","author":"Mitra","year":"2011","journal-title":"Oncogene"},{"key":"2026072409103996300_bib123","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026072409103996300_bib124","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"2026072409103996300_bib125","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"2026072409103996300_bib126","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1021\/acs.bioconjchem.4c00212","article-title":"Reversible chemical modification of antibody effector function mitigates unwanted systemic immune activation","volume":"35","author":"Moquist","year":"2024","journal-title":"Bioconjug. Chem."},{"key":"2026072409103996300_bib127","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: The phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat. Med."},{"key":"2026072409103996300_bib128","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/1078-0432.298.11.1","article-title":"Class III \u03b2-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients","volume":"11","author":"Mozzetti","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"2026072409103996300_bib129","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody\u2013drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"M\u00fcller","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"2026072409103996300_bib130","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pharmthera.2019.05.009","article-title":"Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies","volume":"201","author":"Murai","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"2026072409103996300_bib131","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Nagata","year":"2004","journal-title":"Cancer Cell"},{"key":"2026072409103996300_bib132","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/s41467-024-46167-1","article-title":"Delivery of a BET protein degrader via a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models","volume":"15","author":"Nakazawa","year":"2024","journal-title":"Nat. Commun."},{"key":"2026072409103996300_bib133","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tem.2021.12.003","article-title":"Emerging roles for folate receptor FOLR1 in signaling and cancer","volume":"33","author":"Nawaz","year":"2022","journal-title":"Trends Endocrinol. Metab. TEM."},{"key":"2026072409103996300_bib134","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10549-025-07818-z","article-title":"Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic breast cancer","volume":"214","author":"Nezirevic","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"2026072409103996300_bib135","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"key":"2026072409103996300_bib136","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s11605-012-2105-1","article-title":"TROP2 Correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma","volume":"17","author":"Ning","year":"2013","journal-title":"J. Gastrointest. Surg."},{"key":"2026072409103996300_bib137","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a Novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"2026072409103996300_bib138","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"2026072409103996300_bib223","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a Novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells.","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"2026072409103996300_bib139","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1158\/1538-7445.AM2022-1754","article-title":"Abstract 1754: Amatoxin-based antibody-drug conjugates induce immunogenic cell death and improve the anti-tumor efficacy of immune checkpoint inhibitors in humanized mouse models","volume":"82","author":"Orlik","year":"2022","journal-title":"Cancer Res."},{"key":"2026072409103996300_bib140","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ddtec.2018.08.005","article-title":"Amanitins and their development as a payload for antibody-drug conjugates","volume":"30","author":"Pahl","year":"2018","journal-title":"Drug Discov. Today Technol."},{"key":"2026072409103996300_bib141","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.critrevonc.2025.104787","article-title":"Adverse effect of trastuzumab deruxtecan in solid tumours: A systematic review and meta-analysis","volume":"213","author":"Pathak","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2026072409103996300_bib142","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00358","article-title":"A role for PVRL4-driven cell-cell interactions in tumorigenesis","volume":"2","author":"Pavlova","year":"2013","journal-title":"Elife"},{"key":"2026072409103996300_bib143","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2217\/fon.13.710.2217\/fon.13.7","article-title":"Trastuzumab emtansine: The first targeted chemotherapy for treatment of breast cancer","volume":"9","author":"Peddi","year":"2013","journal-title":"Future Oncol. Lond. Engl."},{"key":"2026072409103996300_bib144","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1038\/s41467-022-30142-9","article-title":"Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer","volume":"13","author":"Pereira","year":"2022","journal-title":"Nat. Commun."},{"key":"2026072409103996300_bib145","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/antib10040042","article-title":"Introduction to antibody-drug conjugates","volume":"10","author":"Pettinato","year":"2021","journal-title":"Antibodies"},{"key":"2026072409103996300_bib146","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: Camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"2026072409103996300_bib147","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000073","article-title":"Twenty years of anti-HER2 therapy-associated cardiotoxicity","volume":"1","author":"Pond\u00e9","year":"2016","journal-title":"ESMO Open"},{"key":"2026072409103996300_bib148","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.neo.2016.11.002","article-title":"Mirvetuximab Soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models","volume":"18","author":"Ponte","year":"2016","journal-title":"Neoplasia"},{"key":"2026072409103996300_bib149","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.taap.2013.09.003","article-title":"Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability","volume":"273","author":"Poon","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"2026072409103996300_bib150","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann. Oncol."},{"key":"2026072409103996300_bib151","doi-asserted-by":"publisher","first-page":"LB227","DOI":"10.1158\/1538-7445.AM2023-LB227","article-title":"Abstract LB227: Leveraging novel Dato-DXd resistance models to inform biomarker discovery and rational combinations to combat drug resistance","volume":"83","author":"Przybyla","year":"2023","journal-title":"Cancer Res."},{"key":"2026072409103996300_bib152","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): Primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026072409103996300_bib225","doi-asserted-by":"publisher","first-page":"S615","DOI":"10.1016\/j.annonc.2025.08.1508","article-title":"939P Phase I, dose-escalation study evaluating safety & efficacy of Trastuzumab Deruxtecan (T-DXd) in combination with ATR inhibitor (AZD6738, Ceralasertib) in advanced solid tumors with HER2 expression (DASH)","volume":"36","author":"Raghav","year":"2025","journal-title":"Ann. Oncol."},{"key":"2026072409103996300_bib154","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2220413120","article-title":"Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers","volume":"120","author":"Rao","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2026072409103996300_bib155","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nature14064","article-title":"Endophilin-A2 functions in membrane scission in clathrin-independent endocytosis","volume":"517","author":"Renard","year":"2015","journal-title":"Nature"},{"key":"2026072409103996300_bib156","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41565-021-00858-8","article-title":"Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics","volume":"16","author":"Rennick","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"2026072409103996300_bib157","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.oraloncology.2007.10.009","article-title":"Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma","volume":"44","author":"Riechelmann","year":"2008","journal-title":"Oral Oncol."},{"key":"2026072409103996300_bib158","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the antibody\u2013drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity","volume":"77","author":"R\u00edos-Luci","year":"2017","journal-title":"Cancer Res."},{"key":"2026072409103996300_bib159","doi-asserted-by":"publisher","first-page":"2","DOI":"10.20517\/cdr.2025.151","article-title":"Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters","volume":"9","author":"Roth","year":"2026","journal-title":"Cancer Drug Resist."},{"key":"2026072409103996300_bib160","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"The Lancet"},{"key":"2026072409103996300_bib161","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1158\/1078-0432.CCR-17-0696","article-title":"Defective cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer","volume":"23","author":"Sabbaghi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"2026072409103996300_bib162","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non\u2013small cell lung cancer with actionable genomic alterations: Results from the phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"2026072409103996300_bib163","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1080\/14712598.2023.2267975","article-title":"Managing adverse events of sacituzumab govitecan","volume":"23","author":"Schlam","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"2026072409103996300_bib164","doi-asserted-by":"publisher","first-page":"S337","DOI":"10.1016\/j.annonc.2023.09.556","article-title":"379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): Updated results from BEGONIA, a phase Ib\/II study","volume":"34","author":"Schmid","year":"2023","journal-title":"Ann. Oncol."},{"key":"2026072409103996300_bib165","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1158\/1538-7445.AM2025-2160","article-title":"Abstract 2160: Trastuzumab deruxtecan induces immunogenic cell death, immune cell activation and -migration in viable human breast cancer slices","volume":"85","author":"Schulte","year":"2025","journal-title":"Cancer Res."},{"key":"2026072409103996300_bib166","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1021\/acs.bioconjchem.4c00534","article-title":"Targeted delivery of TLR7 agonists to the tumor microenvironment enhances tumor immunity via activation of tumor-resident myeloid cells","volume":"36","author":"Sega","year":"2025","journal-title":"Bioconjug. Chem."},{"key":"2026072409103996300_bib167","doi-asserted-by":"publisher","first-page":"oyaf152","DOI":"10.1093\/oncolo\/oyaf152","article-title":"The present and future of precision oncology and tumor-agnostic therapeutic approaches","volume":"30","author":"Shah","year":"2025","journal-title":"The Oncologist"},{"key":"2026072409103996300_bib168","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1038\/s41591-024-03267-1","article-title":"Datopotamab\u2013deruxtecan plus durvalumab in early-stage breast cancer: The sequential multiple assignment randomized I-SPY2.2 phase 2 trial","volume":"30","author":"Shatsky","year":"2024","journal-title":"Nat. Med."},{"key":"2026072409103996300_bib169","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026072409103996300_bib170","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","article-title":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: Exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat. Med."},{"key":"2026072409103996300_bib171","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"2026072409103996300_bib172","doi-asserted-by":"publisher","first-page":"PS13","DOI":"10.1158\/1557-3265.SABCS24-PS13-09","article-title":"Abstract PS13-09: Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling","volume":"31","author":"Sledge","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"2026072409103996300_bib173","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026072409103996300_bib174","doi-asserted-by":"publisher","first-page":"8449","DOI":"10.1158\/1078-0432.CCR-05-1224","article-title":"The novel Poly(ADP-Ribose) Polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks","volume":"11","author":"Smith","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"2026072409103996300_bib175","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1369\/0022155411410430","article-title":"Expression of Trop2 cell surface glycoprotein in normal and tumor tissues","volume":"59","author":"Stepan","year":"2011","journal-title":"J. Histochem. Cytochem."},{"key":"2026072409103996300_bib176","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41392-025-02410-9","article-title":"Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance","volume":"10","author":"Storey","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"2026072409103996300_bib177","doi-asserted-by":"publisher","first-page":"687926","DOI":"10.3389\/fphar.2021.687926","article-title":"Linker design impacts antibody-drug conjugate pharmacokinetics and efficacy via modulating the stability and payload release efficiency","volume":"12","author":"Su","year":"2021","journal-title":"Front. Pharmacol."},{"key":"2026072409103996300_bib178","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody\u2013drug conjugates: Recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"2026072409103996300_bib179","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.pharmthera.2015.08.007","article-title":"Cathepsin L targeting in cancer treatment","volume":"155","author":"Sudhan","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"2026072409103996300_bib180","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1158\/1535-7163.MCT-13-0683","article-title":"The use of olaparib (AZD2281) Potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-Mediated repair of DNA Double-strand breaks","volume":"13","author":"Tahara","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"2026072409103996300_bib181","doi-asserted-by":"publisher","first-page":"104710","DOI":"10.1016\/j.critrevonc.2025.104710","article-title":"WEE1 inhibition in cancer therapy: Mechanisms, synergies, preclinical insights, and clinical trials","volume":"211","author":"Thangaretnam","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2026072409103996300_bib182","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Thomas","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"2026072409103996300_bib183","doi-asserted-by":"publisher","first-page":"LBA109","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study","volume":"43","author":"Tolaney","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"2026072409103996300_bib184","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/1078-0432.CCR-24-1525","article-title":"The mode of action and clinical outcomes of sacituzumab govitecan in solid tumors","volume":"31","author":"Tolaney","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"2026072409103996300_bib185","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"2026072409103996300_bib186","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/onc.2012.36","article-title":"Upregulation of Trop-2 quantitatively stimulates human cancer growth","volume":"32","author":"Trerotola","year":"2013","journal-title":"Oncogene"},{"key":"2026072409103996300_bib187","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat. Commun."},{"key":"2026072409103996300_bib188","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/bcp.15937","article-title":"Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-\u03b1 positive ovarian cancer: The antibody\u2013drug conjugate, payload and metabolite","volume":"90","author":"Tu","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2026072409103996300_bib189","doi-asserted-by":"publisher","first-page":"108503","DOI":"10.1016\/j.jmgm.2023.108503","article-title":"Computational analysis of drug resistance of taxanes bound to human \u03b2-tubulin mutant (D26E)","volume":"123","author":"Uba","year":"2023","journal-title":"J. Mol. Graph. Model."},{"key":"2026072409103996300_bib190","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.annonc.2023.08.005","article-title":"HER2-low expression in patients with advanced or metastatic solid tumors","volume":"34","author":"Uzunparmak","year":"2023","journal-title":"Ann. Oncol."},{"key":"2026072409103996300_bib191","doi-asserted-by":"publisher","first-page":"121802","DOI":"10.1016\/j.lfs.2023.121802","article-title":"Recent advances in using folate receptor 1 (FOLR1) for cancer diagnosis and treatment, with an emphasis on cancers that affect women","volume":"326","author":"Varaganti","year":"2023","journal-title":"Life Sci."},{"key":"2026072409103996300_bib192","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1158\/1078-0432.CCR-23-3414","article-title":"Antibody\u2013drug conjugates: Advancing from magic bullet to biological missile","volume":"30","author":"Veneziani","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"2026072409103996300_bib193","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"2026072409103996300_bib194","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2026072409103996300_bib195","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG Subclasses and allotypes: From structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"2026072409103996300_bib196","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"2026072409103996300_bib197","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/1538-7445.AM2022-1132","article-title":"Abstract 1132: A systems biology approach combining ProLiFiler and cancer data miner for an enhanced preclinical characterization of the WEE-1 inhibitor adavosertib","volume":"82","author":"Vuaroqueaux","year":"2022","journal-title":"Cancer Res."},{"key":"2026072409103996300_bib198","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1039\/D0CS00310G","article-title":"Site-selective modification strategies in antibody-drug conjugates","volume":"50","author":"Walsh","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"2026072409103996300_bib199","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12885-016-2138-z","article-title":"Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification","volume":"16","author":"Wang","year":"2016","journal-title":"BMC Cancer"},{"key":"2026072409103996300_bib200","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/cas.13253","article-title":"Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells","volume":"108","author":"Wang","year":"2017","journal-title":"Cancer Sci."},{"key":"2026072409103996300_bib201","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1158\/1078-0432.CCR-16-1568","article-title":"ABBV-399, a c-met antibody\u2013drug conjugate that targets both MET\u2013amplified and c-met\u2013overexpressing tumors, irrespective of MET pathway dependence","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"2026072409103996300_bib202","doi-asserted-by":"publisher","first-page":"10232","DOI":"10.1038\/s41467-024-54145-w","article-title":"Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"2026072409103996300_bib203","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1186\/s12885-025-14184-y","article-title":"Establishment of a new method for detection of TROP2-positive circulating tumor cells in breast cancer","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"key":"2026072409103996300_bib204","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-drug conjugates (ADCs): Current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol.J Hematol. Oncol."},{"key":"2026072409103996300_bib205","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/1078-0432.CCR-23-1725","article-title":"Spatiotemporal quantification of HER2-targeting antibody\u2013drug conjugate bystander activity and enhancement of solid tumor penetration","volume":"30","author":"Wei","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"2026072409103996300_bib206","doi-asserted-by":"publisher","first-page":"2498162","DOI":"10.1080\/19420862.2025.2498162","article-title":"Homogeneous antibody-drug conjugates with dual payloads: Potential, methods and considerations","volume":"17","author":"Wen","year":"2025","journal-title":"mAbs"},{"key":"2026072409103996300_bib207","doi-asserted-by":"publisher","first-page":"8834","DOI":"10.1021\/acsomega.9b00430","article-title":"Study on the heterogeneity of T-DM1 and the analysis of the unconjugated linker structure under a stable conjugation process","volume":"4","author":"Wu","year":"2019","journal-title":"ACS Omega"},{"key":"2026072409103996300_bib208","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.3390\/cells9071679","article-title":"The ins and outs of cathepsins: Physiological function and role in disease management","volume":"9","author":"Yadati","year":"2020","journal-title":"Cells"},{"key":"2026072409103996300_bib209","doi-asserted-by":"publisher","first-page":"115161","DOI":"10.1016\/j.colsurfb.2025.115161","article-title":"Antibody-drug conjugates (ADCs): \u201cSmart missiles\u201d targeting cancer therapy","volume":"257","author":"Yao","year":"2026","journal-title":"Colloids Surf. B Biointerfaces."},{"key":"2026072409103996300_bib210","doi-asserted-by":"publisher","first-page":"1562167","DOI":"10.3389\/fphar.2025.1562167","article-title":"Targeting the inhibitors of apoptosis proteins (IAPs) to combat drug resistance in cancers","volume":"16","author":"Ye","year":"2025","journal-title":"Front. Pharmacol."},{"key":"2026072409103996300_bib211","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41421-020-0141-7","article-title":"Lysosome biology in autophagy","volume":"6","author":"Yim","year":"2020","journal-title":"Cell Discov."},{"key":"2026072409103996300_bib212","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"2026072409103996300_bib213","doi-asserted-by":"publisher","first-page":"33658","DOI":"10.1038\/srep33658","article-title":"Impact of TROP2 expression on prognosis in solid tumors: A systematic review and meta-analysis","volume":"6","author":"Zeng","year":"2016","journal-title":"Sci. Rep."},{"key":"2026072409103996300_bib214","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.18632\/oncotarget.6733","article-title":"Trop2 is overexpressed in gastric cancer and predicts poor prognosis","volume":"7","author":"Zhao","year":"2015","journal-title":"Oncotarget"},{"key":"2026072409103996300_bib215","doi-asserted-by":"publisher","first-page":"808855","DOI":"10.3389\/fphar.2022.808855","article-title":"HGF\/c-Met: A key promoter in liver regeneration","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"2026072409103996300_bib216","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-023-00573-8","article-title":"Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan","volume":"9","author":"Zhao","year":"2023","journal-title":"Npj Breast Cancer"},{"key":"2026072409103996300_bib217","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.cellsig.2011.08.015","article-title":"The signaling and transformation potency of the overexpressed HER2 protein is dependent on the normally-expressed EGFR","volume":"24","author":"Zhou","year":"2012","journal-title":"Cell. Signal."},{"key":"2026072409103996300_bib218","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1186\/s12885-024-12652-5","article-title":"Landscape of clinical drug development of ADCs used for the pharmacotherapy of cancers: An overview of clinical trial registry data from 2002 to 2022","volume":"24","author":"Zhou","year":"2024","journal-title":"BMC Cancer"},{"key":"2026072409103996300_bib219","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1158\/0008-5472.CAN-23-4099","article-title":"A Dual-Payload Antibody\u2013Drug Conjugate Targeting CD276\/B7-H3 elicits cytotoxicity and immune activation in triple-negative breast cancer","volume":"84","author":"Zhou","year":"2024","journal-title":"Cancer Res."},{"key":"2026072409103996300_bib220","doi-asserted-by":"publisher","first-page":"16964","DOI":"10.1038\/s41598-025-01947-7","article-title":"Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer","volume":"15","author":"Zidel","year":"2025","journal-title":"Sci. Rep."},{"key":"2026072409103996300_bib221","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/bjc.2014.378","article-title":"Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase","volume":"111","author":"Znojek","year":"2014","journal-title":"Br. J. Cancer"}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20252603\/2038551\/jem_20252603.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20252603\/2038551\/jem_20252603.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:10:51Z","timestamp":1784898651000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/223\/8\/e20252603\/282856\/Antibody-drug-conjugates-in-solid-tumors-Efficacy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":222,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20252603","relation":{},"ISSN":["0022-1007","1540-9538"],"issn-type":[{"value":"0022-1007","type":"print"},{"value":"1540-9538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"e20252603"}}